Levee Medical, a medical device company focused on improving outcomes for prostate cancer surgery patients, successfully closed its Series B financing, totaling more than $14 million including note conversions. This fundraising round highlights strong investor confidence in the company’s innovative solution for post-prostatectomy incontinence.
The proceeds will accelerate the development of the Voro® Urologic Scaffold, an absorbable device designed to reduce post-prostatectomy urinary incontinence. The funding will also support ongoing clinical studies, including an upcoming U.S. pivotal trial and current ARID studies.
Related: ImpediMed secures $15m in funding to support SOZO platform
“There is substantial interest in our efforts to help men get drier sooner after surgery. We are deeply grateful for the incredible support we’ve received in bringing transformative solutions to patients and providers,” said Adam Irving, CEO of Levee Medical.
Levee Medical also announced significant milestones in its ARID study. Dr. Gustavo Espino, PI of the ARID study at Hospital Nacional in Panama City, has successfully enrolled 28 patients, contributing to the study’s robust progress. The ARID feasibility study is evaluating the safety and performance of the Voro Urologic Scaffold in reducing post-surgical stress urinary incontinence.
Dr. Espino remarked, “Our experience with the Voro Urologic Scaffold has been extremely encouraging. The device had an outstanding safety profile and patients have noted early improvements in continence, which translates to a considerably better quality of life post-surgery.”
The Voro Urologic Scaffold is designed to be placed during the prostatectomy procedure to manage the geometry of the bladder neck and maintain urethral length, which are critical factors in preventing post-operative incontinence. This innovative, absorbable device aims to markedly reduce the incidence of stress urinary incontinence, providing a much-needed solution for patients undergoing radical prostatectomy.
